Company Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jul 25, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Daniel Barber |
Contact Details
Address: 30 Technology Drive Warren, New Jersey 07059 United States | |
| Phone | 908 941 1900 |
| Website | aquestive.com |
Stock Details
| Ticker Symbol | AQST |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001398733 |
| CUSIP Number | 03843E104 |
| ISIN Number | US03843E1047 |
| Employer ID | 20-8623253 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Barber | Chief Executive Officer, President and Director |
| Lori J. Braender BSBA, Esq., J.D. | Chief Legal Officer, Chief Compliance Officer and Secretary |
| A. Ernest Toth Jr. | Senior Vice President and Chief Financial Officer |
| Cassie Jung | Chief Operating Officer |
| Peter E. Boyd | Senior Vice President of Information Technology and Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2026 | 8-K | Current Report |
| Mar 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 2, 2026 | 8-K | Current Report |
| Jan 21, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 9, 2026 | 8-K | Current Report |
| Nov 17, 2025 | 144 | Filing |
| Nov 14, 2025 | SCHEDULE 13G | Filing |